Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer
One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found t...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2013-01, Vol.6, p.527-530 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 530 |
|---|---|
| container_issue | |
| container_start_page | 527 |
| container_title | OncoTargets and therapy |
| container_volume | 6 |
| creator | Chen, Xue-Hui Li, Zhi-Qiang Peng, Hua Jin, Su-Mei Fu, Hui-Qing Zhu, Tie-Chui Weng, Xiao-Gang |
| description | One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer. |
| doi_str_mv | 10.2147/OTT.S44162 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3660154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2222783166</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-9f14968d1245ab7dddc2a78f241ec685cdaf3e852c02f8b2d78bd97b50c30a243</originalsourceid><addsrcrecordid>eNpdkV1vFSEQhomxsR964w8wJN60Jlv5WmBvmpimWpMmvfCYeEdYYFsqCyvsHnP-fTk5tbblZibMM-8MvAC8x-iUYCY-X69Wpz8Yw5y8AgcYC9nwjqLXT_J9cFjKHUKcS8LegH1CBUJU4ANgVpvJQQx9LEvwsQn-t4M3Of2db-GgzZwyzM64aZuMKSYTUtQB6jj7PtkNPL781eA6-QTO2el5dHGGQ2WDX7sMjY7G5bdgb9ChuHcP8Qj8_HqxOr9srq6_fT__ctUYhvjcdANmHZcWE9bqXlhrDdFCDoRhZ7hsjdUDdbIlBpFB9sQK2dtO9C0yFGnC6BE42-lOSz86a-ouWQc1ZT_qvFFJe_W8Ev2tuklrRTlHuN0KoJ2ATWs3ZVfKs-b_tyaNClPEutpy_DAzpz-LK7MafTEuBB1dWkql2pYJQamo6McX6F1acv3Nokg9QlLMeaU-7SiTUynZDY8rYKS2dqtqt9rZXeEPT1_8iP7zl94D7Gam0g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2222783166</pqid></control><display><type>article</type><title>Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer</title><source>Dove Press Free</source><source>PubMed Central Open Access</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Chen, Xue-Hui ; Li, Zhi-Qiang ; Peng, Hua ; Jin, Su-Mei ; Fu, Hui-Qing ; Zhu, Tie-Chui ; Weng, Xiao-Gang</creator><creatorcontrib>Chen, Xue-Hui ; Li, Zhi-Qiang ; Peng, Hua ; Jin, Su-Mei ; Fu, Hui-Qing ; Zhu, Tie-Chui ; Weng, Xiao-Gang</creatorcontrib><description>One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S44162</identifier><identifier>PMID: 23700371</identifier><language>eng</language><publisher>New Zealand: Taylor & Francis Ltd</publisher><subject>Apoptosis ; hepatocellular carcinoma ; IGF ; IGF-R1 ; Insulin-like growth factors ; Liver cancer ; Monoclonal antibodies ; Original Research</subject><ispartof>OncoTargets and therapy, 2013-01, Vol.6, p.527-530</ispartof><rights>2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013 Chen et al, publisher and licensee Dove Medical Press Ltd 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660154/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660154/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23700371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Xue-Hui</creatorcontrib><creatorcontrib>Li, Zhi-Qiang</creatorcontrib><creatorcontrib>Peng, Hua</creatorcontrib><creatorcontrib>Jin, Su-Mei</creatorcontrib><creatorcontrib>Fu, Hui-Qing</creatorcontrib><creatorcontrib>Zhu, Tie-Chui</creatorcontrib><creatorcontrib>Weng, Xiao-Gang</creatorcontrib><title>Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer.</description><subject>Apoptosis</subject><subject>hepatocellular carcinoma</subject><subject>IGF</subject><subject>IGF-R1</subject><subject>Insulin-like growth factors</subject><subject>Liver cancer</subject><subject>Monoclonal antibodies</subject><subject>Original Research</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkV1vFSEQhomxsR964w8wJN60Jlv5WmBvmpimWpMmvfCYeEdYYFsqCyvsHnP-fTk5tbblZibMM-8MvAC8x-iUYCY-X69Wpz8Yw5y8AgcYC9nwjqLXT_J9cFjKHUKcS8LegH1CBUJU4ANgVpvJQQx9LEvwsQn-t4M3Of2db-GgzZwyzM64aZuMKSYTUtQB6jj7PtkNPL781eA6-QTO2el5dHGGQ2WDX7sMjY7G5bdgb9ChuHcP8Qj8_HqxOr9srq6_fT__ctUYhvjcdANmHZcWE9bqXlhrDdFCDoRhZ7hsjdUDdbIlBpFB9sQK2dtO9C0yFGnC6BE42-lOSz86a-ouWQc1ZT_qvFFJe_W8Ev2tuklrRTlHuN0KoJ2ATWs3ZVfKs-b_tyaNClPEutpy_DAzpz-LK7MafTEuBB1dWkql2pYJQamo6McX6F1acv3Nokg9QlLMeaU-7SiTUynZDY8rYKS2dqtqt9rZXeEPT1_8iP7zl94D7Gam0g</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Chen, Xue-Hui</creator><creator>Li, Zhi-Qiang</creator><creator>Peng, Hua</creator><creator>Jin, Su-Mei</creator><creator>Fu, Hui-Qing</creator><creator>Zhu, Tie-Chui</creator><creator>Weng, Xiao-Gang</creator><general>Taylor & Francis Ltd</general><general>Dove Press</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130101</creationdate><title>Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer</title><author>Chen, Xue-Hui ; Li, Zhi-Qiang ; Peng, Hua ; Jin, Su-Mei ; Fu, Hui-Qing ; Zhu, Tie-Chui ; Weng, Xiao-Gang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-9f14968d1245ab7dddc2a78f241ec685cdaf3e852c02f8b2d78bd97b50c30a243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Apoptosis</topic><topic>hepatocellular carcinoma</topic><topic>IGF</topic><topic>IGF-R1</topic><topic>Insulin-like growth factors</topic><topic>Liver cancer</topic><topic>Monoclonal antibodies</topic><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Xue-Hui</creatorcontrib><creatorcontrib>Li, Zhi-Qiang</creatorcontrib><creatorcontrib>Peng, Hua</creatorcontrib><creatorcontrib>Jin, Su-Mei</creatorcontrib><creatorcontrib>Fu, Hui-Qing</creatorcontrib><creatorcontrib>Zhu, Tie-Chui</creatorcontrib><creatorcontrib>Weng, Xiao-Gang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Xue-Hui</au><au>Li, Zhi-Qiang</au><au>Peng, Hua</au><au>Jin, Su-Mei</au><au>Fu, Hui-Qing</au><au>Zhu, Tie-Chui</au><au>Weng, Xiao-Gang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>6</volume><spage>527</spage><epage>530</epage><pages>527-530</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer.</abstract><cop>New Zealand</cop><pub>Taylor & Francis Ltd</pub><pmid>23700371</pmid><doi>10.2147/OTT.S44162</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2013-01, Vol.6, p.527-530 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3660154 |
| source | Dove Press Free; PubMed Central Open Access; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Apoptosis hepatocellular carcinoma IGF IGF-R1 Insulin-like growth factors Liver cancer Monoclonal antibodies Original Research |
| title | Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A11%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type%201%20insulin-like%20growth%20factor%20receptor%20monoclonal%20antibody%20(HX-1162)%20treatment%20for%20liver%20cancer&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Chen,%20Xue-Hui&rft.date=2013-01-01&rft.volume=6&rft.spage=527&rft.epage=530&rft.pages=527-530&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S44162&rft_dat=%3Cproquest_pubme%3E2222783166%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2222783166&rft_id=info:pmid/23700371&rfr_iscdi=true |